Cas:68089-86-1 (Chloromethyl)triphenylphosphonium iodide manufacturer & supplier

Chemical Name:(Chloromethyl)triphenylphosphonium iodide

CAS.NO:68089-86-1

Synonyms:chloromethyl(triphenyl)phosphanium,iodide;MFCD00051876

Molecular Formula:C₁₉H₁₇ClIP

Molecular Weight:438.67000

HS Code:

Physical and Chemical Properties:

Melting point:210ºC (dec.)

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:13.59000

Exact Mass:437.98000

LogP:1.18080

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like chloromethyl(triphenyl)phosphanium,iodide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00051876 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00051876 Use and application,chloromethyl(triphenyl)phosphanium,iodide technical grade,usp/ep/jp grade.

Related News: Other possible health risks of PFAS include kidney cancer, testicular cancer and high blood pressure, the researchers added. (Chloromethyl)triphenylphosphonium iodide manufacturer Characteristic APIs represented by cardiovascular, antiviral, antitumor and other categories are targeted at generic APIs with patent expiring original research drugs, which have high scientific and technological content and rich profits. They have developed in China in the past decade. The more active API segment has contributed to the rise of Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical. (Chloromethyl)triphenylphosphonium iodide supplier This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care. (Chloromethyl)triphenylphosphonium iodide vendor ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy. (Chloromethyl)triphenylphosphonium iodide factory Characteristic APIs represented by cardiovascular, antiviral, antitumor and other categories are targeted at generic APIs with patent expiring original research drugs, which have high scientific and technological content and rich profits. They have developed in China in the past decade. The more active API segment has contributed to the rise of Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical.